Increasing the use of RWE:  Key European initiatives for 2025

The use of real-world data (RWD) and real-world evidence (RWE) to support pharmaceutical decision making has been a dominant trend over the last decade (ranking as the #1 ISPOR HEOR trend for the last 3 years!¹). RWE is now routinely used to support some regulatory, access and pricing decisions however, scepticism remains, and there is still a feeling that RWE is still underutilised.